An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Silence Therapeutics plc, Nasdaq: SLN, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The Company focuses on precision engineered medicines to silence diseases, aiming to transform people's lives. The event will take place on May 20th, 2:30 p.m. ET, with a live webcast accessible on the Silence website and an archived replay available post-conference.
Silence Therapeutics plc, quotata al Nasdaq con il simbolo SLN, parteciperà a un colloquio informale durante la 2° Conferenza Annuale degli Investitori BioConnect di H.C. Wainwright. L'azienda si concentra su farmaci precision engineered per silenziare le malattie, con l'obiettivo di trasformare la vita delle persone. L'evento si svolgerà il 20 maggio alle 14:30 ET. Sarà possibile seguire la diretta webcast sul sito di Silence, e una registrazione dell'evento sarà disponibile dopo la conferenza.
Silence Therapeutics plc, cotizada en Nasdaq bajo el símbolo SLN, participará en una charla informal en la 2ª Conferencia Anual de Inversores BioConnect de H.C. Wainwright. La compañía se especializa en medicinas de ingeniería de precisión para silenciar enfermedades, con el fin de transformar la vida de las personas. El evento se llevará a cabo el 20 de mayo a las 2:30 p.m. ET, con una transmisión en vivo disponible en el sitio web de Silence y una repetición archivada disponible después de la conferencia.
사일런스 테라퓨틱스 plc, 나스닥 상장 기업(SLN), H.C. 웨인라이트 제2회 연례 바이오커넥트 투자자 콘퍼런스에서 화롯불 대화에 참여할 예정이다. 이 회사는 질병을 침묵시키는 정밀한 약물을 개발하여 사람들의 삶을 변화시키는 것을 목표로 한다. 이 행사는 5월 20일 오후 2시 30분(동부 시간)에 개최되며, 사일런스 웹사이트에서 생중계를 볼 수 있고, 콘퍼런스 이후에는 아카이브된 재방송도 제공될 예정이다.
Silence Therapeutics plc, cotée au Nasdaq sous le symbole SLN, participera à une discussion informelle lors de la 2e Conférence annuelle des investisseurs BioConnect de H.C. Wainwright. L'entreprise se concentre sur les médicaments conçus avec précision pour faire taire les maladies, dans le but de transformer la vie des gens. L'événement aura lieu le 20 mai à 14h30 ET, avec une webdiffusion en direct accessible sur le site de Silence et une rediffusion archivée disponible après la conférence.
Silence Therapeutics plc, an der Nasdaq unter dem Symbol SLN gelistet, wird an einem Kamingespräch auf der 2. jährlichen BioConnect Investorenkonferenz von H.C. Wainwright teilnehmen. Das Unternehmen konzentriert sich auf präzisionsgefertigte Medikamente, um Krankheiten zum Schweigen zu bringen und das Leben von Menschen zu verändern. Die Veranstaltung findet am 20. Mai um 14:30 Uhr ET statt, mit einer Live-Webübertragung auf der Silence-Website und einem archivierten Replay nach der Konferenz.
Positive
None.
Negative
None.
LONDON--(BUSINESS WIRE)--
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20th at 2:30 p.m. ET.
The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and divesiran designed to address hematological diseases, including polycythemia vera. Silence also maintains ongoing research and development collaborations with AstraZeneca and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.
